There is no Zepbound pill. Eli Lilly's weight loss pill is Foundayo (orforglipron), a different medicine taken once a day, while Zepbound (tirzepatide) is a weekly shot. Paying cash at LillyDirect on November 16, 2026, Foundayo is $149 at 0.8 mg; $149 at 2.5 mg until December 31, 2026, then $199; $199 at 5.5 mg until December 31, 2026, then $299; $299 at 9 mg; $349 at 14.5 mg and 17.2 mg, or $299 if you refill within 45 days of your last delivery, and Zepbound is $299 at 2.5 mg, $399 at 5 mg and $449 to $699 at 7.5 mg and up.
No insurance needed. Two programs to check.
Eden$99 a monthWeight loss warranty includedCheck price →
Collective$59 a month, drug priceLowest price on our chartCheck price →
Both come from Eli Lilly and both are approved for weight loss, so the question is pill or shot. They hold different medicines, take different routes and were tested in separate clinical trials.
Foundayo vs Zepbound, side by side
| Foundayo | Zepbound |
|---|---|
| Medicine | |
| Orforglipron | Tirzepatide |
| Sold for cash by | |
| LillyDirect (Eli Lilly) | LillyDirect (Eli Lilly) |
| Approved for | |
| Weight loss in adults with obesity, or with overweight and a weight-related condition | Weight loss in adults with obesity, or with overweight and a weight-related condition. Also moderate to severe obstructive sleep apnea in adults with obesity |
| Cash price | |
| $149 at 0.8 mg; $149 at 2.5 mg until December 31, 2026, then $199; $199 at 5.5 mg until December 31, 2026, then $299; $299 at 9 mg; $349 at 14.5 mg and 17.2 mg, or $299 if you refill within 45 days of your last delivery | $299 at 2.5 mg, $399 at 5 mg and $449 to $699 at 7.5 mg and up |
| How you take it | |
| A tablet once a day | A shot under the skin once a week |
| Savings card, with commercial insurance | |
| As low as $25 for a 1, 2 or 3-month Rx (annual max $1,000), until December 31, 2026 | As low as $25 for a 1, 2 or 3-month Rx (annual max $1,300), until December 31, 2026 |
| Medicare GLP-1 Bridge | |
| $50 a month | $50 a month, Zepbound KwikPen only |
| Doses | |
| 0.8 mg once daily for at least 30 days, then 2.5 mg, then 5.5 mg, then 9 mg, 14.5 mg or 17.2 mg, each after at least 30 days | 5 mg, 10 mg or 15 mg. For sleep apnea, 10 mg or 15 mg. Highest dose 15 mg weekly |
Cash prices are LillyDirect's own, checked November 16, 2026. A Foundayo month is 30 days of tablets. You need a prescription for either.
Why there is no Zepbound pill
Zepbound is tirzepatide, and Lilly sells it only as a weekly shot, in vials or the KwikPen. Lilly's pill for weight loss is Foundayo, which holds a different medicine, orforglipron, made as a small molecule so it can be swallowed.
So someone asking for Zepbound in pill form is choosing between two Lilly drugs, not two forms of one drug. Foundayo's label climbs from 0.8 mg once daily for at least 30 days, then 2.5 mg, then 5.5 mg, then 9 mg, 14.5 mg or 17.2 mg, each after at least 30 days. Zepbound starts at 2.5 mg for 4 weeks and moves to 5 mg after 4 weeks, then 2.5 mg increments after at least 4 weeks on the current dose.
Price by dose at LillyDirect
Foundayo: $149 at 0.8 mg; $149 at 2.5 mg until December 31, 2026, then $199; $199 at 5.5 mg until December 31, 2026, then $299; $299 at 9 mg; $349 at 14.5 mg and 17.2 mg, or $299 if you refill within 45 days of your last delivery. The lower price at 2.5 mg and 5.5 mg runs until December 31, 2026, then $199 and $299.
Zepbound vials: $299 at 2.5 mg, $399 at 5 mg and $449 to $699 at 7.5 mg and up. The $449 price at 7.5 mg and up needs a refill within 45 days of your last delivery; without one, 7.5 mg is $499 and 10 mg and up is $699.
Foundayo has the same kind of rule: its 14.5 mg and 17.2 mg doses drop to $299 with a refill inside 45 days. Every dose: Foundayo cost and Zepbound cost.
Weight loss in the clinical trials
In ATTAIN-1, adults with obesity and no diabetes on Foundayo's top dose lost 11.1 percent of body weight on average at 17.2 mg over 72 weeks, against 2.1 percent on placebo. In SURMOUNT-1, adults on Zepbound's top dose lost 20.9 percent of body weight on average at 15 mg over 72 weeks, against 3.1 percent on placebo.
Both figures count everyone assigned the drug, whether or not they kept taking it. The two drugs were never tested against each other, so the gap is not a head-to-head result. Your prescriber picks the drug and the dose.
Insurance and the savings cards
Both are weight loss drugs, so a plan pays only where it covers weight loss, usually after prior approval. With commercial insurance that covers the drug, Foundayo's card reads as low as $25 for a 1, 2 or 3-month Rx (annual max $1,000), until December 31, 2026. Zepbound's reads as low as $25 for a 1, 2 or 3-month Rx (annual max $1,300), until December 31, 2026. Neither card works with Medicare or Medicaid.
On Medicare, the GLP-1 Bridge charges $50 a month for Foundayo and the Zepbound KwikPen to Part D members who qualify, from July 1, 2026 to December 31, 2027.
Questions people ask
Is there a Zepbound pill?
Is Foundayo cheaper than Zepbound?
Which causes more weight loss, Foundayo or Zepbound?
Are Foundayo and Zepbound the same drug?
Compare other GLP-1 medications
- Ozempic vs Wegovy
- Ozempic vs Mounjaro
- Zepbound vs Ozempic
- Foundayo vs the Wegovy pill
- Tirzepatide vs semaglutide
- Mounjaro vs Zepbound
- Wegovy vs Zepbound
- Wegovy vs Mounjaro
- Is there a generic GLP-1?
- Every GLP-1 medication side by side
- Foundayo cost and Zepbound cost
Sources
Evidence checked November 16, 2026
Every figure above is taken from the document beside it, the FDA label or the trial that produced it, so you can read the source instead of trusting us. How we check sources.
5 documents
- What Foundayo is approved for and its dosesFDA prescribing information for Foundayo (DailyMed, August 2026)
- What Zepbound is approved for and its dosesFDA prescribing information for Zepbound (DailyMed, revised August 2026)
- ATTAIN-1: 11.1 percent of body weight on average at 17.2 mg over 72 weeks, against 2.1 percent on placebo (treatment-regimen average)FDA prescribing information for Foundayo, Table 6, Trial 1 (DailyMed, August 2026)
- ATTAIN-1, the trial paperWharton S et al. N Engl J Med 2025;393(18):1796-1806
- SURMOUNT-1: 20.9 percent of body weight on average at 15 mg over 72 weeks, against 3.1 percent on placeboJastreboff AM et al. N Engl J Med 2022;387(3):205-216
Prices from LillyDirect and Lilly's savings card pages, checked November 16. How we check prices.